Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$147.73
+0.1%
$152.60
$127.59
$187.35
$40.71B0.222.89 million shs3.24 million shs
Globus Medical, Inc. stock logo
GMED
Globus Medical
$85.10
+0.3%
$87.27
$51.79
$101.40
$11.55B11.36 million shs1.88 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$557.21
-0.4%
$566.27
$504.56
$769.98
$43.95B1.58540,626 shs425,070 shs
ResMed Inc. stock logo
RMD
ResMed
$207.80
-0.1%
$219.24
$198.61
$293.81
$30.27B0.841.16 million shs1.70 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.00%+3.79%-2.89%-19.09%-13.84%
Globus Medical, Inc. stock logo
GMED
Globus Medical
0.00%+7.45%-10.75%-7.79%+43.80%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.00%+2.49%-1.16%-13.86%+11.52%
ResMed Inc. stock logo
RMD
ResMed
0.00%+2.00%-5.38%-17.35%-14.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$147.73
+0.1%
$152.60
$127.59
$187.35
$40.71B0.222.89 million shs3.24 million shs
Globus Medical, Inc. stock logo
GMED
Globus Medical
$85.10
+0.3%
$87.27
$51.79
$101.40
$11.55B11.36 million shs1.88 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$557.21
-0.4%
$566.27
$504.56
$769.98
$43.95B1.58540,626 shs425,070 shs
ResMed Inc. stock logo
RMD
ResMed
$207.80
-0.1%
$219.24
$198.61
$293.81
$30.27B0.841.16 million shs1.70 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.00%+3.79%-2.89%-19.09%-13.84%
Globus Medical, Inc. stock logo
GMED
Globus Medical
0.00%+7.45%-10.75%-7.79%+43.80%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.00%+2.49%-1.16%-13.86%+11.52%
ResMed Inc. stock logo
RMD
ResMed
0.00%+2.00%-5.38%-17.35%-14.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.38
Hold$184.8624.41% Upside
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.81
Moderate Buy$106.3624.37% Upside
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.64
Moderate Buy$751.0034.74% Upside
ResMed Inc. stock logo
RMD
ResMed
2.73
Moderate Buy$286.1837.03% Upside

Current Analyst Ratings Breakdown

Latest GMED, IDXX, BDX, and RMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2026
ResMed Inc. stock logo
RMD
ResMed
DowngradeHold (C+)Hold (C)
5/11/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
DowngradeHold (C-)Sell (D+)
5/11/2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
DowngradeHold (C+)Hold (C)
5/11/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Boost Price TargetOverweight$202.00 ➝ $204.00
5/8/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
Lower Price TargetOverweight$104.00 ➝ $103.00
5/8/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Boost Price TargetEqual Weight$157.00 ➝ $161.00
5/8/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
Boost Price TargetOutperform$115.00 ➝ $120.00
5/8/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
Boost Price TargetBuy$114.00 ➝ $117.00
5/7/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Lower Price Target$215.00 ➝ $175.00
5/7/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Boost Price Target$180.00 ➝ $190.00
5/4/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Lower Price TargetHold$189.00 ➝ $163.00
(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$21.84B1.87$23.22 per share6.40$86.24 per share1.72
Globus Medical, Inc. stock logo
GMED
Globus Medical
$2.94B3.95$6.33 per share13.50$34.86 per share2.45
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$4.30B10.22$15.03 per share37.08$19.73 per share28.25
ResMed Inc. stock logo
RMD
ResMed
$5.15B5.91$11.25 per share18.57$44.56 per share4.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.68B$3.9537.6210.8010.455.33%15.37%7.11%8/6/2026 (Estimated)
Globus Medical, Inc. stock logo
GMED
Globus Medical
$537.87M$4.3019.8916.901.7518.92%13.46%11.65%8/6/2026 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$1.06B$13.5841.0433.823.2524.63%70.87%32.56%8/3/2026 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.40B$10.3720.1417.251.3327.44%25.35%18.69%7/30/2026 (Estimated)

Latest GMED, IDXX, BDX, and RMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q2 2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.77$2.90+$0.13-$1.11$4.67 billion$4.71 billion
5/7/2026Q1 2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.92$1.12+$0.20$0.90$740.35 million$759.85 million
5/5/2026Q1 2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.41$3.47+$0.06$3.47$1.12 billion$1.14 billion
4/30/2026Q3 2026
ResMed Inc. stock logo
RMD
ResMed
$2.79$2.86+$0.07$2.74$1.42 billion$1.43 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.202.83%+5.65%106.33%53 Years
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.401.15%+6.33%23.14%13 Years

Latest GMED, IDXX, BDX, and RMD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/28/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.052.81%6/9/20266/9/20266/30/2026
4/30/2026
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.601.18%5/14/20265/14/20266/18/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.62
0.94
0.55
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/A
4.56
2.95
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.19
1.12
0.82
ResMed Inc. stock logo
RMD
ResMed
0.06
3.01
2.33

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.40%
Globus Medical, Inc. stock logo
GMED
Globus Medical
18.38%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.79%
ResMed Inc. stock logo
RMD
ResMed
0.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
72,000275.54 million274.44 millionOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
6,000135.74 million110.80 millionOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00078.88 million78.26 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
10,600145.68 million144.73 millionOptionable

Recent News About These Companies

Why ResMed Sleep Tech Push Is Turning Heads?
ResMed Inc. stock rises Monday, outperforms market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$147.73 +0.10 (+0.07%)
As of 03:58 PM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Globus Medical stock logo

Globus Medical NYSE:GMED

$85.10 +0.29 (+0.34%)
As of 03:58 PM Eastern

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$557.21 -2.16 (-0.39%)
As of 04:00 PM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

ResMed stock logo

ResMed NYSE:RMD

$207.80 -0.25 (-0.12%)
As of 03:58 PM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.